AU1038802A - Protein c or activated protein c-like molecules - Google Patents

Protein c or activated protein c-like molecules

Info

Publication number
AU1038802A
AU1038802A AU1038802A AU1038802A AU1038802A AU 1038802 A AU1038802 A AU 1038802A AU 1038802 A AU1038802 A AU 1038802A AU 1038802 A AU1038802 A AU 1038802A AU 1038802 A AU1038802 A AU 1038802A
Authority
AU
Australia
Prior art keywords
protein
molecules
activated
activated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1038802A
Other languages
English (en)
Inventor
Kim Vilbour Andersen
Anders Hjelholt Pedersen
Per Ola Freskgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen ApS
Maxygen Holdings Ltd
Original Assignee
Maxygen ApS
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen ApS, Maxygen Holdings Ltd filed Critical Maxygen ApS
Publication of AU1038802A publication Critical patent/AU1038802A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AU1038802A 2000-10-18 2001-10-15 Protein c or activated protein c-like molecules Pending AU1038802A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24226800P 2000-10-18 2000-10-18
DKPA200001560 2000-10-18
US30015401P 2001-06-21 2001-06-21
DKPA200100970 2001-06-21
PCT/DK2001/000679 WO2002032461A2 (en) 2000-10-18 2001-10-15 Protein c or activated protein c-like molecules

Publications (1)

Publication Number Publication Date
AU1038802A true AU1038802A (en) 2002-04-29

Family

ID=27439828

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1038802A Pending AU1038802A (en) 2000-10-18 2001-10-15 Protein c or activated protein c-like molecules
AU2002210388A Ceased AU2002210388B2 (en) 2000-10-18 2001-10-15 Protein C or activated protein C like molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002210388A Ceased AU2002210388B2 (en) 2000-10-18 2001-10-15 Protein C or activated protein C like molecules

Country Status (8)

Country Link
US (1) US20030027299A1 (enExample)
EP (1) EP1328622A2 (enExample)
JP (1) JP4071105B2 (enExample)
KR (1) KR20030060915A (enExample)
AU (2) AU1038802A (enExample)
CA (1) CA2425221A1 (enExample)
MX (1) MXPA03003388A (enExample)
WO (1) WO2002032461A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106666A2 (en) * 2002-06-14 2003-12-24 Maxygen Aps Protein c variants with altered properties
AU2003280316A1 (en) * 2002-11-11 2004-06-03 Maxygen Aps Zymogen-like protein c polypeptides
WO2004113385A1 (en) * 2003-06-20 2004-12-29 Maxygen Holdings Ltd. Protein c propeptide variants
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1651252B1 (en) * 2003-07-08 2014-11-26 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
JP4707327B2 (ja) * 2004-01-27 2011-06-22 旭化成ファーマ株式会社 ポリペプタイド類の吸着防止剤
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
ATE474917T1 (de) * 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
EP2103310A1 (en) * 2008-03-19 2009-09-23 Universiteit Maastricht Method for the prevention or treatment of ischemia reperfusion injury.
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
US8916149B2 (en) 2008-11-03 2014-12-23 University Of Rochester Preventing and treating sepsis
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
KR101955884B1 (ko) * 2017-03-17 2019-03-08 주식회사 유비프로틴 단백질 반감기를 증가시키는 방법
KR101893403B1 (ko) * 2017-03-17 2018-08-30 주식회사 유비프로틴 단백질 반감기를 증가시키는 방법
KR101889743B1 (ko) * 2017-03-17 2018-08-20 주식회사 유비프로틴 단백질 반감기를 증가시키는 방법
KR101947339B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Pdgfb 반감기를 증가시키는 방법
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
KR101955886B1 (ko) * 2017-05-05 2019-03-12 주식회사 유비프로틴 안지오포이에틴-1 반감기를 증가시키는 방법
KR101955885B1 (ko) * 2017-05-05 2019-03-08 주식회사 유비프로틴 Pdgfa 반감기를 증가시키는 방법
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270040A (en) * 1985-02-08 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
JP2774154B2 (ja) * 1989-08-10 1998-07-09 帝人株式会社 活性化ヒトプロテインｃ誘導体
AU7168591A (en) * 1989-12-29 1991-07-24 Zymogenetics Inc. Hybrid protein c
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JPH0892294A (ja) * 1994-09-29 1996-04-09 Teijin Ltd ヒト活性化プロテインｃ誘導体
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
ATE321846T1 (de) * 1996-11-08 2006-04-15 Oklahoma Med Res Found Verwendung eines modifizierten protein-c
JP2002542832A (ja) * 1999-04-30 2002-12-17 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
WO2001059084A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
KR20030060915A (ko) 2003-07-16
WO2002032461A2 (en) 2002-04-25
JP4071105B2 (ja) 2008-04-02
US20030027299A1 (en) 2003-02-06
AU2002210388B2 (en) 2006-11-23
EP1328622A2 (en) 2003-07-23
CA2425221A1 (en) 2002-04-25
WO2002032461A3 (en) 2002-09-26
JP2004534503A (ja) 2004-11-18
MXPA03003388A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
GB0001704D0 (en) Protein
AU3662101A (en) Cd40-binding apc-activating molecules
GB0003079D0 (en) Novel protein
GB0011185D0 (en) Protein
GB0024446D0 (en) Protein
IL154999A0 (en) Protein c or activated protein c-like molecules
GB0022670D0 (en) Molecules
GB0009181D0 (en) Protein
GB0002625D0 (en) Dendroaspin molecules
WO2002008423A3 (en) Adhesion molecules
IL150774A0 (en) Apoptin-associating protein
GB0008549D0 (en) Protein
GB0119929D0 (en) Protein
GB0101892D0 (en) Novel protein
GB0001708D0 (en) Protein
GB0011056D0 (en) Protein
GB0015307D0 (en) Protein
GB0031341D0 (en) Protein
GB0008774D0 (en) Protein
GB0030294D0 (en) Protein
GB0014825D0 (en) Protein
GB0001709D0 (en) Protein
GB0030186D0 (en) Protein
GB0011068D0 (en) Molecules
GB0101446D0 (en) Molecules